# A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

> **NCT05258110** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** midazolam
- **DRUG:** iclepertin (BI 425809)

## Key facts

- **NCT ID:** NCT05258110
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-18
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258110, "A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05258110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*